Years later, a disturbing pattern emerged: a handful of children, conceived with sperm from the same anonymous donor, were diagnosed with cancer. Investigators soon traced these cases back to a rare genetic mutation that had slipped through standard screening.
A global donor with nearly 200 children
Denmark has quietly become a powerhouse of the fertility industry. Its sperm banks ship samples to clinics around the world, supplying couples and single parents who cannot conceive without assistance.
Between 2006 and 2022, one anonymous Danish donor, registered under the pseudonym “Kjeld”, became one of the most prolific cases on record. His sperm was sold to 67 fertility clinics in 14 different countries via a major European sperm bank based in Denmark.
According to Danish public broadcaster DR, “Kjeld” is believed to have fathered 197 children worldwide. Ninety-nine of those children were born in Denmark; the rest are spread across Europe and beyond.
Almost 200 children share the same biological father, connected through a donation system that was supposed to be extremely safe.
For many families, this donor made long-awaited pregnancies possible. Yet a small number of these children later developed cancers in early childhood, prompting doctors and regulators to ask whether there could be a common genetic cause.
How the mutation was uncovered
The first alarm reached the sperm bank in April 2020. A child conceived with “Kjeld’s” sperm had been diagnosed with cancer, and genetic testing revealed a mutation in a key gene involved in tumour suppression.
At that point, the finding could have been an isolated case. Fertility clinics and sperm banks handle donations from thousands of men, and not every cancer in a donor-conceived child points back to the donor.
Three years later, another child conceived with sperm from the same donor was found to have cancer linked to the same type of mutation. That second alert changed the picture entirely.
➡️ Was bedeutet eine nach rechts geneigte Handschrift laut Graphologie
➡️ Wie Absicherung gegen Immobilien-Dips mit REITs statt Kauf in Kühlmärkten
➡️ Adieu zu glaskeramik kochfeldern diese trendige alternative bei lidl dürfte für furore sorgen
➡️ Warum viele Menschen falsch gießen – und wie du es deinen Pflanzen leichter machst
➡️ So befreien Sie Ihre Autoscheiben im Winter sekundenschnell mit einem einfachen Hausmittel
The sperm bank ordered an in-depth genetic analysis of the donor’s stored samples. Those tests identified a rare anomaly affecting the TP53 gene, which plays a central role in preventing malignant tumours.
The donor’s mutation had not been picked up by routine screening, despite extensive health checks and laboratory tests.
Once the mutation was confirmed, the bank halted any further use of the donor’s sperm and began notifying clinics and, where possible, affected families. Yet by then, almost two hundred children had already been born.
The “guardian of the genome” gone wrong
What TP53 usually does
The TP53 gene carries the instructions for making a protein called p53. This protein is sometimes described as the “guardian of the genome” because it constantly monitors DNA inside our cells.
When p53 detects DNA damage, it can pause cell division to allow repairs. If the damage is too severe, it can trigger cell death. This process limits the chance that damaged cells will multiply and form tumours.
People born with inherited TP53 mutations are at higher risk of several cancers, often at younger ages. One well-known condition linked to such mutations is Li-Fraumeni syndrome, which dramatically increases the lifetime risk of cancer.
A rare, mosaic mutation
In this Danish case, the mutation was unusual in two ways. First, it was rare and not previously described in scientific databases, according to statements from the European sperm bank involved.
Second, the mutation was mosaic: it appeared only in a subset of the donor’s sperm cells, not across all the cells in his body.
The donor himself does not show signs of disease because the mutation is confined to part of his sperm, not his entire genetic make-up.
This pattern suggests that the mutation occurred at some point during the production of sperm cells, rather than being inherited from the donor’s parents. As a result, standard health checks, blood tests, and even basic genetic screening might easily miss it.
Only some of the sperm cells carried the defective TP53 gene. That means only some of the children conceived from his donations inherited the mutation and the associated cancer risk.
Why existing screening missed the risk
Sperm banks typically follow a multi-step process to assess donors. These checks vary by country and facility, but they often include:
- Detailed medical and family history questionnaires
- Physical examination and blood tests
- Screening for infectious diseases such as HIV and hepatitis
- Basic genetic screening for common inherited conditions (for example, cystic fibrosis)
- Analysis of sperm count, motility and morphology
Advanced genetic sequencing of every donor’s sperm cells is not standard practice. That kind of testing is expensive, complex to interpret, and not yet widely integrated into reproductive medicine.
In the Danish case, the rare TP53 mutation was both previously undescribed and present only in a fraction of the donor’s sperm. Without targeted, high-resolution genetic screening, there was little chance of spotting it in time.
Implications for sperm banks worldwide
This case raises uncomfortable questions for fertility clinics and regulators. A single donor, carrying a hidden mutation, was able to pass on an elevated cancer risk to dozens of children across multiple countries.
Experts are now debating whether current caps on the number of births per donor are strict enough. Some countries limit a donor to around 10–25 families, while others allow higher numbers or rely on voluntary guidelines.
There is also renewed pressure to update genetic screening protocols. Broader testing could catch more inherited conditions, but it also brings ethical and practical dilemmas: where to draw the line, who pays for the tests, and how to handle uncertain findings.
Each extra layer of genetic screening can reduce risk, yet it also adds cost, complexity and difficult choices for clinics and parents.
Families who used this specific donor are now being contacted where possible and may be offered genetic counselling and testing for their children. Even for those who carry the mutation, outcomes can differ widely, and some may never develop cancer.
What parents using donor sperm can do
People considering donor conception often assume that donated sperm has been screened to a very high standard, and that assumption is broadly true. Still, this case shows that zero risk is not realistic.
Prospective parents can take several practical steps when choosing a clinic or bank:
- Ask what genetic tests are performed on donors and how often protocols are updated.
- Check whether the clinic follows national or international limits on the number of births per donor.
- Request written information about how families are notified if a problem is later discovered.
- Discuss with a genetic counsellor if there is a strong history of cancer or rare diseases in their own family.
Some private clinics now offer expanded genetic carrier screening, both for donors and intended parents. This can flag combinations that significantly increase the chance of serious inherited disorders, although it does not catch every possible mutation.
Key terms and real-world scenarios
Understanding mosaicism
The term “mosaicism” describes a situation where different cells in the same person carry different genetic make-ups. In this case, only a fraction of the donor’s sperm cells carried the TP53 mutation.
Mosaicism can arise when a genetic change occurs during cell division after conception. If that change happens in cells destined to form sperm or eggs, it can affect some future children but not others, and leave the parent apparently healthy.
What this could mean for a donor-conceived child
Imagine a child conceived with sperm from a donor later found to carry a rare mutation like this one. Several outcomes are possible:
- The child does not inherit the mutation and has no extra cancer risk from this specific issue.
- The child inherits the mutation and may face an elevated lifetime risk of certain cancers, especially in childhood or early adulthood.
- Regular medical follow-up and screening might pick up any problems earlier, improving treatment options.
Genetic counselling can help families weigh testing decisions, understand probabilities rather than certainties, and manage anxiety that such news can generate. Many children with inherited cancer risk go on to live long lives, especially when health systems are prepared to monitor them closely.
The Danish case is likely to feed into a wider reassessment of how far reproductive medicine should go in scanning for rare genetic changes. As sequencing technology becomes cheaper and more precise, questions about fairness, privacy and the limits of reassurance will only grow sharper.
